Madeline J. Hayes

Madeline J. Hayes

Auto-generated profile, based on publicly available information

Madeline J. Hayes

Department of Pediatrics-Neurology, University of Colorado, Anschutz Medical Campus

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
TBTodd Bartkowiak
Todd Bartkowiak
SLSierra M. Lima
Sierra M. Lima
MHMadeline J. Hayes
Madeline J. Hayes
AMAkshitkumar Mistry
Akshitkumar Mistry
ABAsa A. Brockman
Asa A. Brockman
JIJonathan M. Irish
Jonathan M. Irish
Radiographic contact of glioblastoma (GBM) tumors with the lateral ventricle and adjacent stem cell niche correlates with poor patient prognosis, but the cellular basis of this difference is unclear. Here, we reveal and functionally characterize distinct immune microenvironments that predominate in subtypes of GBM distinguished by proximity to the lateral ventricle. Mass cytometry analysis of isocitrate dehydrogenase wild-type human tumors identified elevated T cell checkpoint receptor expression and greater abundance of a specific CD32 + CD44 + HLA-DR hi macrophage population in ventricle-contacting GBM. Multiple computational analysis approaches, phospho-specific cytometry, and focal resection of GBMs validated and extended these findings. Phospho-flow quantified cytokine-induced immune cell signaling in ventricle-contacting GBM, revealing differential signaling between GBM subtypes. Subregion analysis within a given tumor supported initial findings and revealed intratumor compartmentalization of T cell memory and exhaustion phenotypes within GBM subtypes. Collectively, these results characterize immunotherapeutically targetable features of macrophages and suppressed lymphocytes in GBMs defined by MRI-detectable lateral ventricle contact.

1 July 2022 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
SKSaara Kaviany
Saara Kaviany
TBTodd Bartkowiak
Todd Bartkowiak
DDDaniel E Dulek
Daniel E Dulek
YKYasmin W. Khan
Yasmin W. Khan
MHMadeline J. Hayes
Madeline J. Hayes
JRJeffrey C. Rathmell
Jeffrey C. Rathmell
Patients with STAT1 gain-of-function (GOF) pathogenic variants have enhanced or prolonged STAT1 phosphorylation following cytokine stimulation and exhibit increased yet heterogeneous susceptibility to infections, autoimmunity, and cancer. Although disease phenotypes are diverse and other genetic factors contribute, how STAT1 GOF affects cytokine sensitivity and cell biology remains poorly defined. In this study, we analyzed the immune and immunometabolic profiles of two patients with known pathogenic heterozygous STAT1 GOF mutation variants. A systems immunology approach of peripheral blood cells from these patients revealed major changes in multiple immune cell compartments relative to healthy adult and pediatric donors. Although many phenotypes of STAT1 GOF donors were shared, including increased Th1 cells but decreased class-switched B cells and plasmacytoid dendritic cell populations, others were heterogeneous. Mechanistically, hypersensitivity for cytokine-induced STAT1 phosphorylation in memory T cell populations was particularly evident in response to IL-6 in one STAT1 GOF patient. Immune cell metabolism directly influences cell function, and the STAT1 GOF patients shared an immunometabolic phenotype of heightened glucose transporter 1 (GLUT1) and carnitine palmitoyl transferase 1A (CPT1a) expression across multiple immune cell lineages. Interestingly, the metabolic phenotypes of the pediatric STAT1 GOF donors more closely resembled or exceeded those of healthy adult than healthy age-similar pediatric donors, which had low expression of these metabolic markers. These results define new features of STAT1 GOF patients, including a differential hypersensitivity for IL-6 and a shared increase in markers of metabolism in many immune cell types that suggests a role for STAT1 in metabolic regulation of immunity.

31 July 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
HTHannah L. Thirman
Hannah L. Thirman
MGMadeline J. Grider-Hayes
Madeline J. Grider-Hayes
LGLaura C. Geben
Laura C. Geben
RIRebecca Ihrie
Rebecca Ihrie
BEBrown Lauren E.
Brown Lauren E.
JIJonathan M. Irish
Jonathan M. Irish
A challenge in chemical biology is to study structure-activity relationships (SAR) in vivo in cells. Multiplexed activity profiling (MAP), developed for natural product discovery, is well-suited to address this challenge as it is high throughput, singlecell, and measures multiple hallmark cellular functions. Applying MAP while systematically varying molecular structure (SAR-MAP) could reveal previously unappreciated activity within chemical families and prioritize candidate molecules for further characterization. Here we use SAR-MAP to identify structural features responsible for specific bioactivities of the natural product family, rocaglates. MV411 leukemia cells and healthy human leukocytes are selected for proof-of-concept screening. Testing 600 representative molecules using MAP classifies roughly half of tested rocaglates (9 of 19) as bioactive. SAR-MAP elucidates a methoxy substituent on select rocaglate pyrimidinones as responsible for a desirable anti-leukemia activity. Thus, SAR-MAP can be immediately applied to identify structural variations driving natural product activity in cell lines and primary human cells.

14 July 2023
Verified
Book Chapter
Closed access
HSHenry A M Schares
Henry A M Schares
MHMadeline J Hayes
Madeline J Hayes
JBJoseph A Balsamo
Joseph A Balsamo
HTHannah L Thirman
Hannah L Thirman
BBBrian O Bachmann
Brian O Bachmann
JIJonathan M Irish
Jonathan M Irish

25 February 2026 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
JBJoseph A. Balsamo
Joseph A. Balsamo
HTHannah L. Thirman
Hannah L. Thirman
KPKathryn E. Penton
Kathryn E. Penton
JFJordan Froese
Jordan Froese
BRBenjamin J. Reisman
Benjamin J. Reisman
BBBrian O. Bachmann
Brian O. Bachmann
Natural products derived from biosynthetically apt microorganisms represent an important source for chemotherapeutic agents founded first via non-specific, cytotoxicity-guided isolation, then investigated for translational potential. Analyzing biosynthetic gene clusters within microbes predicts significant untapped potential of undiscovered therapeutically relevant natural products; however, stimulating biosynthesis of such compounds in sufficient quantities for isolation, structure determination, and biological assessment remains a gap. We address this with a bioactivity discovery pipeline that first utilizes Multiplexed Activity Profiling to identify stimulus-dependent induction of bioactive secondary metabolites via functional responses in human leukemia cell lines measured with fluorescence flow cytometry. Next, active extracts are analyzed via Multiplexed Activity Metabolomics, which correlates single cell assays with spectrally defined chromatographic arrays to identify bioactive metabolomic features prior to isolation. Two experimental case studies using this workflow with cave-microbe extracts identified new molecular phenotypes of the pyridine-pyrrolidine alkaloid siderochelin and the pyrrolopyrrole-functionalized anthracycline isoquinocycline B. Finally, we investigated the effects of anthracycline functionalization on human primary cells using single cell mass cytometry to understand if changes in anthracycline aglycon structure and glycosylation impacted cell selectivity. Despite sharing an anthracyclinone pharmacophore core, variants differentially impacted responses of leukemia cell populations within and among acute myeloid leukemia (AML) patient samples. This suggests pharmacophore assumptions may not guide assessment of therapeutic potential for anthracyclines and that modest structural differences can elicit marked changes in cellular function in different patients. Taken together, the depth of information afforded by single cell molecular phenotype-based discovery and mass cytometry deep cell profiling provides new patient-level insight into biological mechanisms of new and previously discovered molecules that may find expanded use in the clinic.

30 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SMStephanie Medina
Stephanie Medina
ABAsa A. Brockman
Asa A. Brockman
CCClaire Cross
Claire Cross
MHMadeline J. Hayes
Madeline J. Hayes
BMBret C. Mobley
Bret C. Mobley
JIJonathan Michael Irish
Jonathan Michael Irish
Adult IDH-wildtype glioblastoma (GBM) is a highly aggressive brain tumor with no established immunotherapy or targeted therapy. Recently, CD32 + HLA-DR hi macrophages were discovered to have displaced resident microglia in GBM tumors that contact the lateral ventricle stem cell niche. Since these lateral ventricle contacting GBM tumors have especially poor outcomes, identifying the origin and role of these CD32 + macrophages is likely critical to developing successful GBM immunotherapies. Here, we identify these CD32 + cells as M_IL-8 macrophages and establish that IL-8 is sufficient and necessary for tumor cells to instruct healthy macrophages into CD32 + M_IL-8 M2 macrophages. Using a set of 73 GBM tumors, IL-8 protein is shown to be present in GBM tumor cells in vivo and especially common in tumors contacting the lateral ventricle. Finally, in ex vivo experiments with conditioned medium from primary human tumor cells, inhibitory antibodies to IL-8 blocked the generation of CD32 + M_IL-8 cells. These results provide a mechanistic origin for CD32 + macrophages that predominate in the microenvironment of the most aggressive GBM tumors. IL-8 and CD32 + macrophages should now be explored as targets in combination with GBM immunotherapies, especially for patients whose tumors present with radiographic contact with the ventricular subventricular zone stem cell niche.